Neurotensin - an Important Regulator of Appetite in Humans?
NCT ID: NCT03522792
Last Updated: 2019-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
18 participants
INTERVENTIONAL
2018-01-05
2019-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study investigates whether the anorexic effects of NT suggested by animal studies can be translated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women
NCT01513499
The Role of Oxytocin-receptor Signalling in Physiological Regulation of Eating Behaviour in Individuals with Obesity
NCT06189001
Oxytocin Effects on Food Motivation Pathways
NCT02276677
Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa
NCT02615119
Endocrine and Neural Control of Eating in Women
NCT02994420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saline + ad libitum meal
This will serve as the placebo / control day for the NT + ad libitum meal study day.
Saline
Intravenous infusion of saline
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
NT + ad libitum meal
Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
Neurotensin
Intravenous infusion of neurotensin
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Saline + liquid meal + ad libitum meal
Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
Saline
Intravenous infusion of saline
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Liquid meal
A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
NT + liquid meal + ad libitum meal
NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
Neurotensin
Intravenous infusion of neurotensin
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Liquid meal
A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
Neurotensin
Acclimatization day
Neurotensin
Intravenous infusion of neurotensin
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neurotensin
Intravenous infusion of neurotensin
Saline
Intravenous infusion of saline
Ad libitum meal
Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
Liquid meal
A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normal haemoglobin levels
* male
* informed consent
Exclusion Criteria
* Familiy history of diabetes mellitus
* Intestinal disease (incl e.g. inflammatory bowel disease and malabsorbtion)
* Family history of inflammatory bowel disease
* Previous intestinal resection
* Body mass index (BMI) over 25 kg/m2
* Smoker
* Nephropathy (S-creatinine\> 130 μM)
* Liver disease (ALAT and/or ASAT \> 2 × upper normal limit)
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Copenhagen University Hospital, Hvidovre
OTHER
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simon Veedfald
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hvidovre University Hospital
Hvidovre, Capital, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Neurotensin BMI/HH 2017 UCPH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.